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Abstract
Conventional central chondrosarcoma (CCC) is a malignant bone tumor that is characterized by the production of
chondroid tissue. Since radiation therapy and chemotherapy have limited effects on CCC, treatment of most patients
depends on surgical resection. This study aimed to identify the expression profiles of microRNAs (miRNAs) and isomiRs
in CCC tissues to highlight their possible participation to the regulation of pathways critical for the formation and
growth of this type of tumor. Our study analyzed miRNAs and isomiRs from Grade I (GI), Grade II (GII), and Grade III (GIII)
histologically validated CCC tissue samples. While the different histological grades shared a similar expression profile
for the top abundant miRNAs, we found several microRNAs and isomiRs showing a strong different modulation in GII
+ GIII vs GI grade samples and their involvement in tumor biology could be consistently hypothesized. We then in
silico validated these differently expressed miRNAs in a larger chondrosarcoma public dataset and confirmed the
expression trend for 17 out of 34 miRNAs. Our results clearly suggests that the contribution of miRNA deregulation,
and their targeted pathways, to the progression of CCC could be relevant and strongly indicates that when studying
miRNA deregulation in tumors, not only the canonical miRNAs, but the whole set of corresponding isomiRs should be
taken in account. Improving understanding of the precise roles of miRNAs and isomiRs over the course of central
chondrosarcoma progression could help identifying possible targets for precision medicine therapeutic intervention.
Introduction
Chondrosarcomas are a heterogeneous group of
malignant bone tumors that are characterized by the
production of a cartilage matrix1. Chondrosarcoma is the
second most frequent primary malignant bone tumor
after osteosarcoma2. The vast majority (85%) are con-
ventional central chondrosarcomas (CCCs), which occur
mainly in adulthood/old age, from an intramedullary
location and most frequently involve the bones of the
trunk, the pelvis, femur or humerus. The site and the
histological grade of the tumors, based on criteria such as
the presence of matrix changes, high cellularity, nuclear
atypia, binucleation, mitotic rate, and necrosis, are cur-
rently the main prognostic factors, and in particular,
histological grade is the single most important predictor
of local recurrence and metastasis. Well-differentiated
tumors with poor cellularity (low grades), classified as
Grade I, are only locally aggressive, have good prognosis
after surgical resection (commonly intralesional cur-
ettage) with 5-year survival rates of 90%; while poorly
differentiated tumors with high cellularity (high grades),
classified as Grade II and III, are associated with high
metastatic potential with 5-year survival of 53%3–6.
Chondrosarcomas are unresponsive to chemotherapy and
radiotherapy and, to date, surgery is the treatment of
choice (in order to prevent recurrence and metastasis,
wide en-bloc excision is the preferred surgical treatment
in Grade II and III cases)7.
MicroRNAs (miRNAs) are a class of regulatory non-
coding small RNA molecules that control many biological
pathways at post-transcriptional level and are involved in
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cancer progression8,9. Regulatory miRNAs are able to
repress their targets by an imperfect base pairing between
the seed sequence at the miRNA 5′ end and the com-
plementary sites in the 3′-untranslated region (3′-UTR) of
the target messenger RNAs (mRNAs). MiRNAs modulate
target gene expression through translational repression or
mRNA cleavage10. It is estimated that miRNAs are
responsible for the regulation of translation of about
30–60% of human genes11. Changes in miRNA expression
are associated with tumor progression and metastases,
and miRNAs have been proposed as biomarkers for
diagnosis and prognosis of various cancer types. More-
over, several studies showed that a single miRNA locus
may transcribe and process not only the canonical
miRNA sequence, but also a cluster of multiple miRNA
isoforms (isomiRs) with expression, length, and sequence
heterogeneities12,13. It has been shown that the isomiR
expression diverges across different tissues, cell types, and
developmental stages12.
Defining the CCC miRNA landscape is highly important
and may reveal diagnostic and therapeutic markers and/or
targets suitable to improve current chondrosarcoma
precision medicine treatments. The aim of the present
study was to investigate the involvement of miRNAs and
isomiRs in a small but accurately selected CCC cohort to
increase the knowledge about the miRNAs and miRNA-
regulated pathways contributing to tumorigenesis in this
pathology.
Results
miRNA expression in CCC
Small RNA next-generation sequencing (NGS) was
performed on a cohort of nine histologically validated
CCCs (Fig. 1), comprising two Grade I (GI), three Grade II
(GII), and four Grade III (GIII) cases (Table 1). It is well
known that the clinical course of Grade I patients is
diverse from Grade II and III3,4,14, thus, we decided to
analyze our small cohort of patients comparing the GI
cases to the GII and GIII together.
Sequencing libraries were prepared from the small RNA
fraction of the samples, size-selected to be enriched for
miRNA fractions and then sequenced on a SOLiD 5500xl
platform. After excluding low-quality reads and trimming
adaptor sequences, the remaining reads were first mapped
to the human genome (GRCh38/hg38) and then to miR-
base (v21), to annotate known miRNAs in each sample.
An average expression level of 0.001% was set as a
threshold to exclude poorly expressed miRNAs. Using
this threshold, we identified a total of 290 miRNAs
expressed across all the CCC samples analyzed and
reported in Supplementary Information (Table S1).
Fig. 1 Multiple chondroid nodules from GI treated with curetage. a, b Macroscopic features; c microscopic features showing permeative growth
patterns of GI CCC; d hypocellular cartilage and occasional binucleation (Arrow). GII CCC of proximal femoral shaft. e Macroscopic features on cut
surface that show cartilaginous tumor with focal chalk-like gritty areas. f, g Microscopic features showing aggressive growth patterns of CCC with
permeation of intertrabecular spaces within intramedullary cavity and intermediate power photomicrographs showing mixoid matrix and immature
hypercellular cartilage. GIII CCC of femoral shaft. h Macroscopic features on cut surface. i, j Microscopic appearance of aggressive growth patterns
with permeation of lamellar bone, showing marked increase in cellularity, nuclear atypia, binucleation, multinucleation, stromal myxoid changes, and
spindling of chondrocytes.
Table. 1 Clinical information of the patients analyzed.
Patient ID Location Grade
1 10–777 Proximal humerus WHO I
2 05–1568 Sacro WHO I
3 06–1147 Proximal humers WHO II
4 10–1374 Sacroiliac joint WHO II
5 09–2231 Proximal fibula WHO II
6 08–769 Proximal humerus WHO III
7 04–356 Proximal humerus WHO III
8 09–330 Proximal fibula WHO III
9 09–608 Ischiopubic branch WHO III
Age range 25–79, 4 female and 5 male.
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Figure 2 shows the 20 most abundantly expressed
miRNAs for GI, GII, and GIII samples, ordered according
their abundance calculated as percentage of all the miR-
NAs expressed in each group. For all the three grades,
these top 20 miRNAs represented over 80% of all the
miRNA counts. Interestingly, we observed that most of
the top 20 miRNAs were the same in all the three grades.
Among them, miR-140-3p was the most abundant
miRNA in GII (47.5%) and GIII (23.4%) groups and the
second most abundant in GI samples (18.3%), where the
most abundant miRNA was miR-451a (21.8%).
Nonetheless, when considering the globally most
expressed miRNAs in the whole dataset, GII and GIII
cases showed a more similar profile with respect to GI
cases, which clustered apart as shown in Supplementary
Information (Fig. S1).
Remarkably, when looking at miRNAs with a strong
different expression level in GII+GIII vs GI cases of our
collection (|log2FC|>2), we found 34 miRNAs, including
24 more- and 10 less-abundant in GII+GIII vs GI cases
(even if only one -hsa-miR-489-3p- reaching statistical
significance (FDR-BH < 0.1) due to small sample size)
(Table 2). Among them, we noticed the presence of miR-
451a, which we described above as one of the top 20 of all
the three grades and the most abundant miRNA in GI
group. Here, with a log2FC of −2.6, it was one of the
miRNAs whose expression was most reduced in GII+
GIII vs GI samples.
Using Diana Tools TarBase15, we determined the
mRNAs targeted by these 34 strongly differently expres-
sed miRNAs and analyzed the main pathways they are
involved in using Reactome Pathways Database16. Table
3A, B displays the pathways enriched by the genes tar-
geted by the miRNAs found more and less expressed,
respectively, in our GII+GIII vs GI cases. Among the
pathways targeted and, as consequence, probably inhib-
ited by the more expressed miRNAs, we mainly found: (i)
immune regulatory signaling, such as interferon signaling
and ER-phagosome pathways; (ii) adhesion signaling, such
as syndecan interactions; (iii) regulation of RUNX1
expression (Table 3A). Conversely, the less expressed
miRNAs were able to target and control the signaling
pathways of FGFR, ERK, and WNT (Table 3B).
In silico miRNA validation in a chondrosarcoma public
dataset
To validate the 34 miRNAs with a strong different
expression level in our GII+GIII vs GI grade CCC
samples, we analyzed the recently published miRNA
sequencing data of a larger chondrosarcoma dataset
including GI, GII, and GIII grade cases.
Globally, out of the 34 miRNAs strongly differently
expressed in our samples, seven miRNAs resulted under the
expression threshold (at low level of expression also in our
case series) and thus not expressed in the public dataset (hsa-
miR-136-5p, hsa-miR-144-3p, hsa-miR-144-5p, hsa-miR-31-
3p, hsa-miR-376a-5p, hsa-miR-4284, hsa-miR-489-3p).
Among the other 27 miRNAs passing the expression
threshold, while seven miRNAs showed no expression
difference (|log2FC|<0.5) in GII+GIII vs GI grade sam-
ples of the public dataset, 17 miRNAs confirmed the trend
of modulation of their expression we found in our sam-
ples, even if always with a smaller fold-change value
(Fig. 3). On the other hand, three miRNAs showed a
modulation trend opposite to that observed in our dataset
(hsa-miR-206, hsa-miR-133a-3p, hsa-miR-146a-5p). The
highly expressed hsa-miR-451a confirmed its expression
reduction in GII+GIII vs GI samples also in the public
dataset, and here with a statistically significant FDR value
(FDR-BH= 0.02).
Fig. 2 The 20 most abundant miRNAs expressed in Grade I, Grade II, and Grade III central chondrosarcomas. The colored sectors of the pie-
charts identify each miRNA in Grade I (GI), Grade II (GII), and Grade III (GIII) CCC samples. The percentage of expression reported for each miRNA is
calculated on the total miRNAs identified in each group.
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IsomiRs of the differently modulated miRNAs
Most miRNAs can have sequence and length variability,
potentially resulting in altered targeting capacity and/or
specificity. These isoforms (termed isomiRs) differ from
the canonical mature miRNA sequences, as deposited in
the miRBase, by the addition or trimming of nucleotides
at either end and may also carry internal nucleotide
substitutions13,17,18.
Globally, by small RNA next-generation sequencing and
by applying an ad hoc bioinformatics pipeline, we
Table 2 List of miRNAs differently modulated in GII+GIII vs GI CCCs.
Mean GI Mean GII+ GIII Log2FC (GII+ GIII) vs GI p-Value FDR-BH
hsa-miR-206 5.76 163.17 4.82 0.0452 0.56
hsa-miR-31-3p 3.71 47.59 3.68 0.0455 0.56
hsa-miR-539-5p 11.46 120.21 3.39 0.1733 0.80
hsa-miR-382-5p 42.82 392.61 3.20 0.2301 0.80
hsa-miR-31-5p 443.79 4027.37 3.18 0.0599 0.63
hsa-miR-154-5p 14.26 121.08 3.09 0.3019 0.80
hsa-miR-335-5p 69.42 563.24 3.02 0.0226 0.50
hsa-miR-296-5p 13.30 96.01 2.85 0.0039 0.19
hsa-miR-337-5p 29.08 202.89 2.80 0.1986 0.80
hsa-miR-323b-3p 13.86 95.72 2.79 0.2853 0.80
hsa-miR-379-5p 56.51 370.55 2.71 0.2880 0.80
hsa-miR-133a-3p 4.59 29.96 2.71 0.0210 0.50
hsa-miR-487b-3p 45.91 297.36 2.70 0.3172 0.80
hsa-miR-127-3p 34.01 214.65 2.66 0.3235 0.80
hsa-miR-323a-3p 20.00 121.45 2.60 0.3016 0.80
hsa-miR-376a-5p 19.63 116.84 2.57 0.3179 0.80
hsa-miR-329-3p 18.64 108.40 2.54 0.3207 0.80
hsa-miR-134-5p 65.72 367.31 2.48 0.4159 0.80
hsa-miR-299-5p 20.03 108.46 2.44 0.3034 0.80
hsa-miR-337-3p 55.00 284.17 2.37 0.3529 0.80
hsa-miR-136-5p 39.08 197.20 2.34 0.4154 0.80
hsa-miR-409-3p 112.71 545.22 2.27 0.3481 0.80
hsa-miR-485-3p 14.34 66.37 2.21 0.3792 0.80
hsa-miR-369-5p 12.70 52.10 2.04 0.4218 0.80
hsa-miR-142-5p 3066.08 762.90 −2.01 0.0277 0.50
hsa-miR-378c 1792.81 431.96 −2.05 0.0029 0.19
hsa-miR-20b-5p 397.40 89.68 −2.15 0.0391 0.52
hsa-miR-4284 142.31 30.78 −2.21 0.0801 0.72
hsa-miR-144-3p 1469.84 312.46 −2.23 0.0700 0.67
hsa-miR-144-5p 1064.99 219.75 −2.28 0.0322 0.51
hsa-miR-106a-5p 78.37 16.17 −2.28 0.0142 0.43
hsa-miR-451a 218299.38 36740.32 −2.57 0.0179 0.46
hsa-miR-146a-5p 503.56 76.59 −2.72 0.0039 0.19
hsa-miR-489-3p 495.25 27.07 −4.19 0.0004 0.05
Mean of the normalized counts (CPM) for each group and log2 fold-change (log2FC) are reported. P-values and false discovery rate (corrected by Benjamini–Hochberg
method, FDR-BH) were calculated by EdgeR exact test method. Significant FDR < 0.1.
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identified a total of 1576 isomiRs expressed across our
nine CCC samples.
Considering the 34 canonical miRNAs with a strong
different expression level in our GII+GIII vs GI CCCs
reported in Table 2, and setting a threshold of mean
expression >0.001% to exclude poorly expressed isomiRs,
we identified a total of 57 different isomiRs deriving from
15 miRNAs across the nine CCC cases. They are reported
together with their normalized read counts (counts per
million, CPM) and sequences in the Supplementary
Information (Table S2A), while the isomiR naming rules
we implemented here are described in the Supplementary
Information (Table S2B).
The expression values for the isomiRs of each miRNA
were extremely variable and characteristic of the indivi-
dual miRNA they derive from. There were miRNAs with
many highly expressed different isomiRs, such as the
aforementioned miR-451a (with 26 isomiRs), and miR-
NAs with no isomiRs at all (19 out of the 34 canonical
miRNAs had no isomiR passing expression threshold
(mean >0.001%)).
Altogether, the cumulative expression of all the 57 iso-
miRs corresponding to the differently modulated miRNAs
represent the 21.9%, 2.4%, and 4.7% of all the isomiRs
expressed in GI, GII, and GIII samples, respectively.
Among them, the isomiRs of miR-451a were collectively
the most abundant in each grade, even if with a different
abundance (21.3% in GI, 2.1% in GII, 4.1% in GIII).
Moreover, if considering individual isoforms, one isomiR
of miR-451a resulted the most abundant isoform over all
the isomiRs expressed in GI group (hsa-miR-451a.3.P0.
S.57: 14.8% in GI vs 1.6% in GII, 3% in GIII).
Regarding the frequency of the various modifications
shown by each individual miRNA, 3′-end variations have a
marked preponderance being common to all samples
(Table S2A). On the other hand, nine isomiRs deriving from
hsa-miR-142-5p, hsa-miR-144-3p, hsa-miR-337-3p, hsa-
miR-409-3p, and has-miR-4284 carried the more critical 5′-
end shift, mostly represented by the insertion/deletion of
one or two C, in some cases coupled with a 3′-end shift.
Next, similarly to what done with canonical miRNAs,
we considered among these 57 isomiRs those showing a
strongly different expression level in our GII+GIII vs GI
CCCs (|log2FC|>2). Globally, we found 55 isomiRs,
including 16 more and 39 less expressed in GII+GIII vs
GI cases (Fig. 4). All these isomiRs maintained the
expression trend (up- or down-) of the miRNA they derive
from. Interestingly, two isoforms of hsa-miR-31-5p
showed the higher expression increase, while all the 26
isomiRs of hsa-miR-451a showed a reduction in our GII
+GIII vs GI grade cases, with 12 isoforms being the most
down-expressed (log2FC <−3). Moreover, the reduced
expression of 11 of these hsa-miR-451a isomiRs resulted
statistically significant (FDR-BH < 0.1).
Then, by using the latest version of MicroRNA Target
Prediction Database (miRDB) online database (http://
mirdb.org/), we identified the putative target genes spe-
cific of these isomiRs. Those genes already recognized by
the corresponding canonical miRNAs were excluded from
the pathway analysis, thus considering only the nine iso-
miRs targeting a different set of genes. Interestingly, all
these isomiRs were those showing a 5′-end variation.
Finally, by using the latest version of Reactome Pathways
Database (https://reactome.org/), we defined that the
pathways affected only by this specific set of isomiRs in
Table 4 are reported the most important pathways dif-
ferently targeted by this set of isomiRs, many of which are
related to oncogenic signaling.
Discussion
In the current study, a systematic also if somewhat
limited small RNA profiling was performed to identify the
miRNAs and isomiRs expressed in a small cohort of nine
histologically validated and reliably graded conventional
central chondrosarcoma tumors. The miRNA profiles of
CCC samples were produced by small RNA next-
generation sequencing technology and analyzed by
focusing our attention on miRNAs distinguishing
advanced GII and GIII cases from GI patients, in order to
highlight any possible tumor progression-linked altera-
tion. This study concerns only the microRNAs, neglecting
all the other species of small and long non-coding RNAs
that could participate, both directly and indirectly, in
regulating gene expression.
We identified 290 miRNAs expressed across all the
CCC samples analyzed. The analysis of the 20 most
abundantly expressed miRNAs in Grade I, Grade II, and
Grade III cases showed that they represent about 80% of
the total miRNA counts.
The most abundant miRNA in all histological grades of
CCC was hsa-miR-140-3p, thus resulting not significantly
altered by tumor progression. It is known that this
miRNA is positively regulated by the transcription factor
Sox9 during cartilage differentiation19,20. Other two
miRNAs highly expressed in all grades were hsa-miR-23b-
3p, known for contributing to chondrocyte differentia-
tion21, and hsa-miR-21-5p, which is one of the commonly
overexpressed miRNAs in cancer and is an oncomiR
regulating cell proliferation, migration, invasion, and drug
resistance22. We also found two miRNAs most abun-
dantly expressed in GI tumors, which are hsa-miR-451a
and hsa-miR-16-5p. These miRNAs possess oncosup-
pressor properties: hsa-miR-16-5p targets SMAD3 in
chondrocytes23,24, while hsa-miR-451 has tumor sup-
pressor activity in many cancers25 and decreases cell
chemoresistance targeting MDR1 gene26.
Considering the other miRNAs, hsa-miR-99a-5p is
associated with poor prognosis in acute myeloid leukemia
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(AML) and its ectopic expression upregulates genes that
are downstream targets of E2F and MYC and that are
critical for stem cells maintenance and cell cycle27. Hsa-
miR-103a-5p targets the known tumor suppressor
transcription factor KLF4 in many cancers, including
colorectal cancer28; moreover, it belongs to a group of
miRNAs with mechanosensitive properties and is
involved in bone formation and differentiation29. The let-
Fig. 3 In silico validation of the canonical miRNAs found modulated in our GII+GIII vs GI grade samples. Expression modulation of each
miRNA is reported as log2 fold-change value as calculated in GII+ GIII vs GI grade cases of our sample collection (black bars) and of a
chondrosarcoma public dataset (white bars). *FDR-BH < 0.1.
Fig. 4 Differently modulated isomiRs in our GII+ GIII vs GI CCC cases. Expression modulation of each isomiR is reported as log2 fold-change
value. IsomiR names follow nomenclature rules described in Table S2B. *FDR-BH < 0.1.
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7f-5p miRNA has been found to inhibit apoptosis and to
promote chemotherapeutic resistance in some
tumors30,31.
The most less expressed miRNAs we found in our GII
+GIII tumors as compared with GI cases (Log2FC <
−2.5) included hsa-miR-451a, hsa-miR-146a-5p, and hsa-
miR-489-3p (even if not reaching statistical significance
probably due to the limited number of cases). According
to our data these less expressed miRNAs have tumor
suppressor function in many tumor types25,32,33 and
mainly participate to biological pathways involved in
apoptosis, in the downregulation of ERBB2 signaling, of
MAP kinase activation, transmembrane receptors that
regulate cell migration, the degradation of GLI2/3 tran-
scription factors, insulin receptor signaling and WNT
signaling. These pathways, all endowed with established
oncogenic potential, would be enhanced in advanced
tumors where the expression of their regulating miRNAs
was strongly reduced, thus supporting the establishment
of the tumor malignant phenotype. In particular, the
canonical WNT signaling pathways has been implicated
in the β-catenin-dependent regulation of mitotic and cell-
fate-determining gene transcription of osteoarthritis34.
The Dickkopf WNT signaling pathway inhibitor 1
(DDK1) gene, an antagonist of canonical WNT/β-catenin
signaling, and β-catenin were progressively overexpressed
in chondrosarcoma tissues with increasing histological
grade and correlated with poor prognosis35. Targeting of
WNT signaling has been proposed as being of interest for
chondrosarcoma therapeutic treatment.
On the other hand, when analyzing the miRNAs with a
higher expression in GII+GIII cases as compared with
GI tumors, the most increased miRNAs (Log2FC > 3)
included hsa-miR-206, hsa-miR-31-3p, hsa-miR-539-5p,
hsa-miR-382-5p, hsa-miR-31-5p, hsa-miR-154-5p, and
hsa-miR-335-5p. The most interesting pathways targeted
by these miRNAs were (i) apoptotic execution phase; (ii)
syndecan interactions; (iii) interferon signaling; (iv) reg-
ulation of RUNX1 expression and activity. Interferons are
a family of cytokines able to trigger a potent anti-viral
response in the cells36. Syndecans are a small family of
heparan sulfate pro-teoglycans, which are involved in
different pathologies including cancer. Syndecans have
been recently involved in tumor progression. For example,
syndecan-1 acts as a tumor suppressor in breast cancer
cells37,38. As well, some authors found that syndecan-4
inhibited breast carcinoma cell invasion and was asso-
ciated with good prognosis39,40. On the other hands,
contrasting findings are reported since the expression of
syndecan-4 has been found correlated with negative
estrogen receptor status41. RUNX proteins are transcrip-
tion factors crucial for development and normal tissue
homeostasis and have been reported as both oncogene
and tumor suppressors in different tumors42. RUNX1
expression decrease is also correlated with the loss of its
oncosuppressor function and the induction of epithelial-
mesenchymal transition43.
Interestingly, hsa-miR-451a, which is the less expressed
miRNAs in the high-grade group of our small set of
chondrosarcoma, was also significantly validated with the
same trend of modulation in the public dataset. Hsa-miR-
451a, when expressed at low level in chondrosarcoma
could represent a potential biomarker capable of detecting
GI cases from the more advanced GII and GIII and help
to choice the surgical strategy often critical in the man-
agement of these patients.
Each individual miRNA exists as a set of naturally
occurring sequence variants, called isomiRs, differing from
the canonical sequence by 3′- and/or 5′-end length varia-
tions and also internal nucleotide modifications. These
subtle sequence variations can have profound effects on
miRNA function. With regard to the frequencies of the
various isomiR modification types shown in this study,
marked preponderance of 3′-end variations is common to
all tumor samples of our collection, while the more critical
5′-end shifts are less frequent. The nucleotide modifica-
tions, either alone or in combination with end shifts, are
quite frequent, accounting for almost one-third of total
isomiRs. Although many isomiRs may affect the same
downstream targets as their canonical sequences44, 3′-end
modifications mainly modulate miRNA processing, stabi-
lity and targeting effectiveness45–48, while 5′-end mod-
ifications altering the seed sequence affect miRNA
targeting specificity. Analyzing the behavior of this latter
group of isomiRs we observed that the expression of six of
them was lower, while in two cases was higher in GII+
GIII vs GI tumors. Studying the genes targeted by the set
of less expressed isomiRs we found that many of the
pathways targeted by these isomiRs are correlated with
oncogenic signaling. Our findings suggest that this sets of
isomiRs collaborate with the canonical miRNAs to repress
these tumor-linked pathways.
One of the targets of the hsa-miR-142-5p isoforms is
CD44, which is a tumor stem cell marker and receptor for
hyaluronan, collagens, and matrix metalloproteinases in
various tissues acting also as a cofactor for VEGF and
FGF2 binding. Concordantly, CD44 expression is reported
as increasedin chondrosarcomas and correlates with the
increasing grading and metastatic potential49. It is to note
that the hsa-miR-142-5p is also significantly modulated
with the same decreasing trend in the public dataset.
The isomiR-4284.53.P0.S.12, which is less expressed in
our dataset, targets TGF-β family members, known to be
involved in a wide range of cellular processes, such as
proliferation, differentiation, migration, and death. They
are key regulators of normal chondrogenesis, and this
signaling pathways may be involved in the development
and progression of central chondrosarcoma. In addition,
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other authors demonstrated that TGF-β signaling is
higher in high-grade chondrosarcoma than in low-grade
chondrosarcoma50,51. In the same way, isomiR-4284.53.
P0.S.12 and the hsa-miR-142-5p isoforms, all down-
regulated in our dataset, target the activation of Gamma-
aminobutyric acid (GABA) receptor. GABA, being a
neurotrophic factor shows a crucial function in the
development of neural crest, thus playing important
functional roles in the proliferation of chondrosarcoma
cells, which are derived from neural crest cells52. The less
expressed isomiR-4284.53.P0.S.12 targets also the activa-
tion of Rac1 pathway. Rac1 is a Rho GTPases regulating
many intracellular signaling pathways, including those
involved in tumorigenesis, invasion, and metastasis. It has
been also demonstrated that the overexpression of Rac1
resulted in an accelerated tumorigenic process in color-
ectal cancer as well as in other solid tumors53,54.
There are several publications in the literature that
describe the behavior of miRNAs in CCC. To facilitate the
comparison with our data we have listed them in the
Supplementary Information (Table S3), reporting only the
publications dealing with tumor tissues, with an evalua-
tion of their agreement with our findings.
In conclusion, this study, although involving a small
number of patients, suggests that the contribution of
miRNA deregulation to the progression of CCC could be
important and strongly indicates that when studying
miRNA deregulation in tumors, not only the canonical
miRNAs, but the whole set of corresponding isomiRs
should be taken in account.
Materials and methods
Study cohort and patient characteristics
Specimens used for small RNA next-generation
sequencing consisted of fresh-frozen tumor tissues from
nine patients (listed in Table 1), diagnosed with primary
CCC from the Department of Surgical Pathology at the
ASST Orthopaedic Traumatology Centre Gaetano Pini-
CTO, Milan, Italy. The enrolled patients were re-
evaluated by two sarcoma pathologists (A.P. and E.A.)
and the lesions were histologically classified in accordance
with the World Health Organization (WHO) classification
of soft tissue and bone tumors 2002/201355.
Patients were included in this study based on a histological
diagnosis of Grade I—low grade, low cellularity, mostly
chondroid matrix, with uniform hyperchromatic plump
nuclei with occasional binucleations56; Grade II—high grade,
increased cellularity, nuclear atypia, hyperchromasia, and
nuclear size; Grade III—high grade, high cellularity, nuclear
pleomorphism with mitoses present (Fig. 1).
The study was approved by the institutional Internal
Review Board (Department of Surgical Pathology of the
ASST (Local Health and Social Care Company) Ortho-
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Italy, Protocol, ASST# HUM00026026). Informed consent
was obtained from all patients prior to biopsy. Eligibility
criteria for the study include patients before surgery and
from surgical resection. Clinical features, imaging and
histological data were used without any information
linked to patients’ identities. Local radiographs were
performed at each evaluation.
Open biopsies were snap frozen in optimal cutting
temperature (OCT), and longitudinal sections were cut.
Hematoxylin and eosin-stained frozen sections were
reviewed by the study pathologists (A.P. and E.A.) to
identify cores with the highest tumor content that were
subsequently used for nucleic acid extraction.
RNA isolation
Total RNA was isolated from human chondrosarcoma
tissue samples embedded in OCT compound using Trizol
reagent (Thermofisher), according to the manufacturer’s
protocol, and the RNA concentration was measured by
NanoDrop1000 Spectrophotometer (ThermoFisher Sci-
entific, Waltham, MA, USA). The RNA quality was
checked by 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA) using an Agilent RNA 6000 Nano kit and
shown in the Supplementary Information (Fig. S2).
Small RNA library construction and next-generation
sequencing
Total RNA samples (about 3 µg each) were enriched for
small RNAs up to 200 bp by size selection using the Flash-
Page small RNA Isolation Kit (Ambion, Thermofisher) and
miRNA quality and enrichment was assessed by the 2100
Bioanalyzer (Agilent Technologies) using a Agilent Small
RNA kit. Enriched RNA samples were processed using the
Small RNA Expression Kit (Applied Biosystems, Thermo-
Fisher Scientific), according to the manufacturer’s protocol.
Briefly, RNA was first hybridized and ligated with the adapter
mix “A”, subsequently reverse transcribed and treated with
RNAse H. The cDNA libraries were then PCR amplified,
purified and size-selected by PAGE, resulting in libraries
containing inserted small RNA sequences of 20–40 bp. Size,
integrity and purity of the libraries were verified by the 2100
Bioanalyzer (Agilent Technologies), using the DNA 1000 kit.
The cDNA libraries were barcoded using the SOLiD RNA
barcoding kit and amplified onto beads using emulsion PCR.
Templated beads were deposited on slides and sequenced
using the Applied Biosystems SOLiD 5500xl Sequencer,
obtaining about 40 millions of 50-bp reads per sample.
Quantification of known microRNAs
The qualified clean reads were mapped and analyzed
with the ‘small RNA’ bioinformatics pipeline from the
Lifetech Lifescope version 2.5.1 software, using as a target
the human genome GRCh38/hg38 and the dataset of
mature and precursor miRNA sequences (miRBase,
release 21)57. Any sequence match against repetitive ele-
ments of the genome (SINE, LINE, etc.), and against non-
miRNA small RNAs (snoRNAs, piRNAs, tRNAs, rRNA
fragments, etc.) were filtered out from the results.
Sequence counts were extracted and reformatted with
Perl scripts from the pipeline output. Differential
expression analysis of our high- vs low-grade CCC cases
was performed by comparing GII+GIII cases to GI cases
using the EdgeR Bioconductor package (v.3.28.1) in R
environment (v.3.6.0)58. miRNAs with mean normalized
count per million (CPM) < 10 across all the nine samples
were discarded to exclude poorly expressed genes. After
having estimated the tagwise dispersion, genewise exact
test59 as implemented in EdgeR was used to measure the
statistical significance of differential expression. MiRNAs
were defined as significantly differentially expressed if
their false discovery rate (p-value corrected for multiple
comparison with the Benjamini–Hochberg procedure
(FDR-BH)) was <0.1.
Identification and differential expression of isomiRs
The alignment files in BAM format corresponding to
the same biological group were merged and converted to
SAM (Sequence Alignment/Map) format with samtools60.
The files were then processed and analyzed with the
miRDeep2 software for miRNA prediction61. The differ-
ential expression analysis for isomiRs was carried out by
EdgeR Bioconductor package, with the same analytical
strategy described previously (significant FDR-BH < 0.1).
In silico validation in a chondrosarcoma public dataset
Canonical miRNAs identified in our CCC cases were
validated in a recently published dataset including 73
human chondrosarcoma samples of different grades
sequenced for miRNA profile by Illumina technology (E-
MTAB-7265)3. After downloading and quality control of
fastq files, reads were adapter trimmed, filtered, and
mapped on the human reference genome GRCh38/hg38
by using miRDeep2 tool (v.0.1.3). The same tool was used
to generate raw counts for mature known miRNAs
annotated in miRBase 21. Raw counts were imported in
EdgeR Bioconductor package (v.3.28.1) and used to per-
form a differential expression analysis of GII+GIII (n=
56) vs GI (n= 17) cases, similarly to what done for our
cases. miRNAs with mean CPM < 10 across the whole
public dataset were discarded before testing for statistical
significance. A FDR-BH < 0.1 was set as threshold to
define statistically significant differentially expressed
miRNAs in high- vs low-grade cases of the public dataset.
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